- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.09. | H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution | 3 | Investing.com | ||
| 17.09. | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | 2 | Insider Monkey | ||
| 14.09. | Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday | 7 | Benzinga.com | ||
| 14.09. | Cantor Fitzgerald reiterates Tyra Biosciences stock rating | 1 | Investing.com | ||
| 14.09. | Cantor Fitzgerald bestätigt "Overweight"-Rating für Tyra Biosciences Aktie | 1 | Investing.com Deutsch | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.09. | Tyra Biosciences prices $400 million stock offering | 1 | Investing.com | ||
| 14.09. | Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs | 1 | Seeking Alpha | ||
| 14.09. | Tyra Biosciences platziert Kapitalerhöhung über 400 Millionen US-Dollar | - | Investing.com Deutsch | ||
| 09.09. | Why Is Tyra Biosciences Stock Sinking Wednesday? | 1 | Benzinga.com | ||
| 09.09. | Tyra Biosciences Stock Plunges 22% Despite Positive Bladder Cancer Data | 1 | RTTNews | ||
| 09.09. | Tyra Biosciences Aktie stürzt nach Phase-2-Studienergebnissen um 30 % ab | 4 | Investing.com Deutsch | ||
| 09.09. | Tyra Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09. | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | 306 | PR Newswire | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| 08.09. | Piper Sandler reiterates Tyra Biosciences stock rating ahead of data | 20 | Investing.com | ||
| 08.09. | H.C. Wainwright reiterates Tyra Biosciences stock rating at buy | 2 | Investing.com | ||
| 04.09. | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | 2 | Seeking Alpha | ||
| 04.08. | Tyra Biosciences GAAP EPS of -$0.69 misses by $0.04 | 2 | Seeking Alpha | ||
| 04.08. | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | 318 | PR Newswire | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| 10.06. | BofA raises Tyra Biosciences stock price target on safety outlook | 3 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | Qiagen-Aktie: Was die Spuren im Labor verraten - Warren Wise Podcast | Ein verlässliches Geschäft mit einer Zukunftsgeschichte, die Fragen aufwirft. Qiagen liefert den ersten Handgriff vieler molekularer Untersuchungen: Das Unternehmen löst Erbgut aus Blut, Gewebe oder... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -0,02 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| ADARX PHARMACEUTICALS | 18,250 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,125 | +0,12 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-0,15 %) liegt der Kurs bei 20,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.